JP Morgan Initiates Coverage On N-able with Overweight Rating, Announces Price Target of $17
JP Morgan initiates coverage on N-able (NYSE:NABL) with a Overweight rating and announces Price Target of $17.
N-able Sees Q3 Sales $86.5M-$87M, Sees FY21 Sales $343M-$345M
Financial Outlook for the Third Quarter of 2021
N-able management currently expects to achieve the following results for the third quarter of 2021:
Total revenue in the range of $86.5 to $87.0 million, representing
Needham Initiates Coverage On N-able with Buy Rating, Announces Price Target of $17
Needham analyst Mike Cikos initiates coverage on N-able (NYSE:NABL) with a Buy rating and announces Price Target of $17.
62 Biggest Movers From Yesterday
Gainers
NeuroMetrix, Inc. (NASDAQ: NURO) shares surged 208% to settle at $10.04 on Tuesday as the company said it received FDA breakthrough device designation for the treatment of fibromyalgia with its wearable neurostimulation technology.